Refractory Angina - Pipeline Insight, 2024

This “Refractory Angina - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Refractory Angina pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Refractory Angina Understanding

Refractory Angina: Overview

Refractory angina (RA) is conventionally defined as a chronic condition (=3 months in duration) characterised by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischaemia has been clinically established to be the cause of the symptoms. There is a sensation of pressure or pain in the chest that is the result of insufficient blood flow to the heart muscle and in which treatment with medication and heart surgery is either insufficient or no longer effective. Patients have reproducible lifestyle-limiting symptoms of chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis that makes revascularization problematic.

Refractory Angina - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Angina pipeline landscape is provided which includes the disease overview and Refractory Angina treatment guidelines. The assessment part of the report embraces, in depth Refractory Angina commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Angina collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Angina R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Angina.

Refractory Angina Emerging Drugs Chapters

This segment of the Refractory Angina report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Refractory Angina Emerging Drugs

XC001: XyloCor TherapeuticsXC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status and results in a poor quality of life because of the associated chest pain caused by the ischemia when even moderate physical exertion occurs. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain. An Investigational New Drug (IND) application for XC001 is open with the FDA. XyloCor commenced this Phase 1/2 trial in refractory angina in early 2020.

IMB-101: Imbria pharmaceticalsIMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. Currently, it is in phase II stage of development to treat refractory angina.

Refractory Angina: Therapeutic Assessment

This segment of the report provides insights about the different Refractory Angina drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Refractory Angina

There are approx. 3+ key companies which are developing the therapies for Refractory Angina. The companies which have their Refractory Angina drug candidates in the most advanced stage, i.e. phase II include, Imbria pharmaceticals.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Refractory Angina pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Refractory Angina: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory Angina therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Angina drugs.

Refractory Angina Report Insights

• Refractory Angina Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Refractory Angina Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Refractory Angina drugs?
• How many Refractory Angina drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory Angina?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Refractory Angina therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Refractory Angina and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• XyloCor Therapeutics
• Imbria pharmaceticals
• Angionetics Inc.

Key Products

• XC001
• IMB-101
• Ad5FGF-4